Bernstein's Lance Wilkes on UnitedHealth's Q4 results, state of the health insurance industry
Lance Wilkes, Bernstein senior equity analyst, joins 'Squawk Box' to discuss UnitedHealth's quarterly earnings results, state ...
Long-term market trends remain in very good shape, says Fundstrat's Mark Newton
Mark Newton, Fundstrat Global head of technical strategy, joins 'Squawk Box' to discuss the latest market trends, state of ...
CNBC's Kernen Rips Paul Ryan In Interview: Now You're Calling For Unity, You Sound Like A Democrat
In an interview with Paul Ryan on Thursday, CNBC 'Squawk Box' host Joe Kernen called him out for saying that he wants unity after the election. Kernen told him it would "would have been nice" to say ...
Mediaite7h
Joe Kernen Mocks Paul Ryan to His Face for Sounding ‘Like a Democrat’: ‘A Vote Not for Trump Was a Vote for Kamala Harris!’
Former Speaker of the House Paul Ryan joined Squawk Box on Wednesday for a segment in which he was ruthlessly mocked by host Joe Kernen.
Kalshi names Donald Trump Jr. as strategic adviser to prediction market firm
The president-elect’s eldest son growing business footprint now includes the prediction market platform that rose to ...
Sports Business Journal3d
Marc Lasry talks sports investment strategy and identifying opportunities
Avenue Capital Group CEO Marc Lasry joined CNBC's 'Squawk Box' to discuss his take on the sports world and explained how he ...
Crypto Briefing2d
SEC Chair Gary Gensler says Bitcoin is speculative but likens it to gold
SEC Chair Gary Gensler compares Bitcoin to gold, calling it speculative, as he discusses crypto regulation and ETFs before ...
decrypt2d
Departing SEC Chair Gary Gensler Slams Crypto Again—But Says Bitcoin Is Different
As crypto’s sheriff prepares to hang up his spurs, SEC Chair Gary Gensler took the opportunity to separate Bitcoin from the ...
Tom Lee Forecasts Bitcoin Could Dip To $50K, But Maintains Long-Term Target Of $250K Amid Market Volatility
Wall Street strategist Tom Lee suggests Bitcoin (CRYPTO: BTC) could retreat significantly from recent highs, potentially ...
Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’Day
Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...
Andrew Left Challenges Federal Charges: 'That's Not Manipulation'
Citron Research founder Andrew Left addresses federal charges of fraud and market manipulation, sparking debates on free speech and trading practices.